A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

NCT02553889 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

End-stage Renal Disease (ESRD)

Interventions

DRUG: ISIS 416858
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.

Collaborators

[object Object]